阿立哌唑与舒必利治疗老年精神分裂症临床对照观察

目的 探讨阿立哌唑治疗老年精神分裂症的疗效与安全性。方法 将80例老年精神分裂症患者随机分为研究组（阿立哌唑治疗）和对照组（舒必利治疗），每组40例，观察8周。用阳性和阴性综合征量表（PANSS）和不良反应量表（TESS）分别评定临床疗效和不良反应。结果 在治疗8周末，2组临床疗效无显著性差异；2组在治疗2周后PANSS评分均较治疗前显著下降（P〈0．05或P〈0．01），同期比较，2组间无显著性差异；研究组TESS评分明显低于对照组（P〈0．01）。结论 阿立哌唑治疗老年精神分裂症疗效较好，与舒必利相当，但不良反应少而轻微，临床使用安全，有利于提高治疗依从性。

Clinical study of aripiprazole and sulpiride in treatment of senile schizophrenia

Objective To explore the efficacy and safety of aripiprazole in treatment of senile schizophrenia. Methods Eighty patients with senile schizophrenia were randomly assigned to two groups treated with aripiprazole（ study group） or sulpiride（ control group） respectively for 8 weeks. The positive and negative syndrome scale（PANSS） and treatment emergent side effect scale （TESS） were used to evaluate the efficacy and adverse effect respectively. Results The clinical efficacy had no significant difference between the two groups. The scores of PANSS in two groups after treatment were significantly lower than those before treatment. But the scores of PANSS had no significant difference between the two groups. The incidence of adverse effect in the study group was significantly lower than that in the control group. Conclusions Aripiprazole is as effective as sulpiride in treatment of senile schizophrenia. But it is much safer than sulpiride.